Table 4.
Univariate analyses for PFS and OS in 29 TKIs-treated NSCLC patients with tumor tissue EGFR mutation
| PFS | OS | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (years) | 0.036 | 0.117 | ||||
| ≤60 | 0.412 | 0.166-1.026 | 0.215 | 0.024-1.925 | ||
| >60 | Reference | Reference | ||||
| Gender | 0.677 | 0.704 | ||||
| Male | 1.192 | 0.492-2.887 | 1.395 | 0.233-8.366 | ||
| Female | Reference | Reference | ||||
| Smoking history | 0.477 | 0.491 | ||||
| Smoker | 1.388 | 0.528-3.650 | 1.817 | 0.303-10.882 | ||
| Never smoker | Reference | Reference | ||||
| Tumor type | 0.091 | 0.783 | ||||
| Adenocarcinoma | 0.197 | 0.023-1.685 | 21.242 | 0.000-4.270E+15 | ||
| Non-adenocarcinoma | Reference | Reference | ||||
| Lymph node metastasis | 0.191 | 0.414 | ||||
| Yes | 3.265 | 0.435-24.515 | 24.012 | 0.000-5.071E+06 | ||
| No | Reference | Reference | ||||
| Tumor stage | 0.981 | 0.505 | ||||
| II-III | 0.983 | 0.225-4.303 | 0.043 | 0.000-90661.512 | ||
| IV | Reference | Reference | ||||
| Plasma EGFR mutation | 0.157 | 0.019 | ||||
| Positive | 1.818 | 0.741-4.460 | 66.307 | 0.050-88082.845 | ||
| Negative | Reference | Reference | ||||